Articles By Jack Cush, MD
Building a Better Rheumatologist
Are you efficient, productive and accurate in what you do? Could you be better? Or do the job differently?
Read Article
Obamacare Deficient in Rheumatologists, Other Specialists
The October 27 issue of JAMA reports a study of federal marketplace insurance plans shows roughly 15 percent completely lacked in-network physicians for at least one specialty, a practice found among multiple states and issuers.
Read Article
High Level Skin Responses Seen with Inhibitor of IL-23p19 in Psoriasis
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Read Article
FDA Panel Votes 10-4 to Approve Lesinurad for the Treatment of Hyperuricemia/Gout
Despite concerns over safety, the FDA Arthritis Advisory Committee voted favorably to approve lesinurad (LES) at a meeting held Friday, October 23, 2015. Overall, panel members felt the potential benefits of LES outweighed the safety concerns reviewed by the FDA presenters.
Read Article
Vertebral Fractures in 10% of Spondyloarthritis Patients
Vertebral fractures are not uncommon in patients with ankylosing spondylitis and spondyloarthritis.
Read Article
IV Cyclophosphamide Equal to Mycophenolate in Lupus Nephritis
A comparison of mycophenolate mofetil (MMF) and low-dose cyclophosphamide IV (CYC) in the treatment of lupus nephritis (LN) was examined in 173 patients with class III, IV, or V LN.
Read Article
Increasing Placebo Responses in the USA
A recent analysis of randomized clincal trials (RCT) for the treatment of neuropathic pain has shown in increase in placebo responses. (Citation source http://buff.ly/1LL8yAi)
Read Article
U.S. Pays 10 Times More for Prescription Drugs than Other Countries
Prescription drugs may cost up to 10 times more in the United States than they do in other countries, according to a 2013 Comparative Price Report was released last month by the International Federation of Health Plans (IFHP).
Read Article
FDA Reviews the Safety of Lesinurad in Gout
Lesinurad is a novel URAT-1 inhibitor being developed as a urate-lowering therapy for gout by Astra-Zeneca.
Read Article
Weight Loss Improves Skin Outcomes in Psoriasis
A recent presentation at the European Academy of Dermatology and Venereology (EADV) meeting in Copenhagen showed the long-term outcomes of weight loss in psoriasis.
Read Article
